Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer

Crizotinib, a small molecule inhibitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and c-MET (also called MET or hepatocyte growth factor receptor), has been approved by the Food and Drug Administration for the treatment of patients with advanced non-small cell lung cancer whose tum...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Transl Res
Hlavní autoři: Huang, Xiao-Xiu, Xie, Feng-Feng, Hou, Li-Jiao, Chen, Xiu-Xiu, Ou, Rong-Ying, Yu, Jiang-Tao, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Yang, Yang, Zheng, Di-Wei, Chen, Yao, Huang, Jia-Rong, Wang, Kun, Wei, Meng-Ning, Li, Wen-Feng, Shi, Zhi, Yan, Xiao-Jian
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5411916/
https://ncbi.nlm.nih.gov/pubmed/28469773
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky